Stroke clinical overview

Send This

Download

Comment

Favourite

more

Rating :

Rate It:

Embed :

Post a comment

Post Comment on Twitter Post Comment on SlideWorld

Comments:

Subscribe to follow-up comments

5 Favorites

Hui-Chun3Lf, favourited this 4 Months ago.

gphookan, favourited this 4 Months ago.

patricialorenzoc, favourited this 1 Years ago.

janmejays, favourited this 1 Years ago.

fssharthy, favourited this 4 Years ago.

First Prev [1] Next Last

Notes

Hide Notes

Slide 1 :

Clinical Overview Director, Stanford Stroke Center Stanford University Palo Alto, California Gregory W. Albers, MD

Slide 2 :

Ischemic Stroke 85% of strokes are ischemic Most ischemic strokes caused by atherosclerosis of extracranial or intracranial arteries Embolic or thrombotic occlusion of cerebral blood vessels by aggregated platelets, fibrin, and debris from atheromatous plaques

Slide 3 :

The Most Frequent Sites of Arterial and Cardiac Abnormalities Causing Ischemic Stroke Intracranial Atherosclerosis Carotid Plaque With Arteriogenic Emboli Aortic Arch Plaque Cardiogenic Emboli Penetrating Artery Disease Flow Reducing Carotid Stenosis Atrial Fibrillation Valve Disease Left Ventricular Thrombi Albers et al, Chest, 1998.

Slide 4 :

Transient Ischemic Attack Transient occlusion of an intracranial artery due to thromboembolism Symptoms resolve following rapid fragmentation and dissolution of the microemboli/thrombus

Slide 5 :

Stroke Morbidity and Mortality Leading cause of serious, long-term disability Third leading cause of death in the U.S.; second leading cause worldwide Accounts for >50% of all hospitalizations for acute neurologic disease

Slide 6 :

Stroke Incidence >700,000 new or recurrent strokes per year ~ 4 million Americans are living with neurologic deficits due to stroke

Slide 7 :

The High Cost of Stroke Annual Total 1998 Per Event* Direct Costs $28B $38,714 (care and treatment) Indirect Costs $15B $20,520 (lost productivity) Total $43B $59,234 *Based on 731,000 strokes/yr American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas, TX:AHA, 1997. Broderick J et al. Stroke. 1998;29:415–421.

Slide 8 :

Secondary Prevention of Ischemic Stroke Carotid endarterectomy: >50% stenosis Anticoagulation therapy: Cardioembolic stroke Antiplatelet therapy: Most common therapy

Slide 9 :

Antiplatelet Agents for Stroke Prevention Aspirin Ticlopidine Clopidogrel Dipyridamole

Slide 10 :

Patient Relative Risk Odds Population Therapy Reduction (%) Reduction (%) Efficacy of Antiplatelet Agents for Prevention of Stroke, MI, or Vascular Death All Vascular All antiplatelet 22 27 Diseases regimens Stroke/TIA All antiplatelet 17 22 regimens Stroke/TIA Aspirin 13 16 Source: Antiplatelet Trialists’ Collaboration, 1994: Algra and Van Gijn 1996. Risk Reductions

Slide 11 :

Efficacy of Antiplatelet Agents vs Placebo for Prevention of Stroke, MI, or Vascular Death in Stroke/TIA Patients Aspirin (all doses) 10 13 Ticlopidine 1 23 Dipyridamole + ASA 4 30 All Antiplatelet Agents 18 17 Relative Risk Antiplatelet Agent No. of Studies Reduction (%) Source: Algra and Van Gijn 1996; Gent et al. 1989; Tijssen, 1998; Antiplatelet Trialists’ Collaboration, 1994.

Slide 12 :

Algra and van Gijn (1996) J Neurol Neurosurg Psychiatr 60:197–199. 0.4 60% 0.6 40% 0.8 20% 1 0% 1.2 -20% 1.4 -40% 1.6 -60% RR and 95% CI ASA ? 100 mg (2 Studies) ASA ? 900 mg (7 Studies) ASA 300 mg (1 Study) ALL (10 Studies) RR = 13% RR = 9% RR = 14% RR = 13% Low vs Med: P = 0.75 Low vs High: P = 0.99 Med vs High: P = 0.71 Relative Risk Reductions for Vascular Death, Stroke, MI from ASA Trials vs Placebo in Stroke/TIA Patients

Slide 13 :

Stroke or Death at 3 Months Stroke, MI, or Death at 3 Months 0 1 2 3 4 5 6 7 8 9 10 Low-Dose (N = 1395) (81 or 325 mg) High-Dose (N = 1409) (650 or 1300 mg) Event Rate (%) 5.7% 6.2% 7.1% 8.4% P = 0.030 P = 0.120 Taylor DW, Thorpe KE, for the ACE Trial Study Group. Presented at The Challenge of Stroke; The Lancet Conference; October 15–16, 1998. Montreal, Quebec, Canada; 1998. ACE TRIAL Aspirin Efficacy by Dose Prevention of Vascular Events Following Carotid Endarterectomy

Slide 14 :

FDA Recommends Low-Dose Aspirin FDA reviewed trials of aspirin vs placebo The “positive findings at lower dosages are sufficient reason to lower the dosage of aspirin...for subjects with TIA and ischemic stroke.” For “ischemic stroke and TIA: 50 to 325 mg [aspirin] once a day. Continue therapy indefinitely.” FDA, Federal Register. 1998.63:56802–56819.

Slide 15 :

New Aspirin Dosing Guidelines for Secondary Stroke Prevention FDA New professional labeling for aspirin recommends 50 to 325 mg/day American College of Chest Physicians Aspirin at 50 to 325 mg/day as an initial choice American Heart Association [50–325 mg/day proposed]

Slide 16 :

Available Antiplatelet Agents Ticlopidine Advantages Proven efficacy in patients having suffered an ischemic stroke (compared with placebo) Proven efficacy in patients having suffered a TIA or minor stroke (compared with high-dose ASA) Disadvantages Risk of neutropenia Risk of thrombotic thrombocytopenic purpura (TTP) Require CBC monitoring Diarrhea/Rash

Slide 17 :

Available Antiplatelet Agents (Cont’d) Clopidogrel Advantages Proven efficacy compared with ASA in patients with stroke, MI, or PAD Well-tolerated Disadvantages Efficacy for TIA not proven Not more efficacious than ASA in the stroke and myocardial infarction subgroups

Slide 18 :

Relative Risk Reduction vs Aspirin 7% 21%* 9% 23%* 22%* 8% 0 5 10 15 20 25 Stroke Stroke/MI/Vascular Death† Relative Risk Reduction (%) Clopidogrel (CAPRIE, N = 6431) Ticlopidine (TASS, N = 3069) ER-DP + ASA (ESPS-2, N = 3299) Efficacy of Antiplatelet Agents in Patients With Cerebrovascular Disease * Statistically significant. † Represents stroke/MI/Sudden Death for ESPS-2.

Slide 19 :

Albers GW et al. Chest. 1998;114:683S–698S. ACCP Antiplatelet Guidelines “Every patient who has experienced a [non-cardioembolic] stroke or TIA...should receive an antiplatelet agent.…” “Aspirin, clopidogrel...ticlopidine..., and the combination of aspirin and dipyridamole are all acceptable options for initial therapy.” “Clopidogrel is recommended in favor of ticlopidine because it has a lower incidence of significant adverse effects.” “The combination of dipyridamole and aspirin b.i.d. may be more effective than clopidogrel and has a similarly favorable adverse effect profile.”

Slide 20 :

Summary and Conclusions Antiplatelet agents are effective in the secondary prevention of non-fatal stroke and death Currently approved antiplatelet regimens provide a modest reduction in risk More effective and safe treatment options for stroke prevention and its devastating consequences are needed

Slide 21 :

Slide 22 :

Risk Reductions Relative Risk: Rate of events on drug A Rate of events on drug B Odds Ratio: # of pts with event on drug A # of pts with event on drug B # of pts without event on drug A # of pts without event on drug B 100 patients treated for 1 year: 5 strokes on drug A, 10 strokes on drug B Relative Risk: 5% = .50 Relative Risk = 50% 10% Reduction (1-relative risk) Odds Ratio: 5 10 = .47 Odds Reduction = 53% 95 90 (1-odds ratio) ? ?

PTCA Clinical Trial

The Long QT Syndrome...

Heart Disease, Hyper...

Error in Patient Car...

Immunizations 101 A ...

Falls and Stroke

Free Powerpoint Templates

	flintoff 5 Years ago.



11240 Views, 6 favourite
PowerPoint Slide Presentation on
More By User Flag as inappropriate Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details. Cancel